|
A daunting challenge
Ron Cohen is the CEO of Acorda Therapeutics,
Inc. (Hawthorne, New York), a company dedicated
to finding cures for SCI. But he is quick to acknowledge that fixing SCI
is no small matter. "Someone has taken a hatchet to the major power
grid cable coming into New York City," he says. "An engineering
tour de force is required."
Cohen’s realism comes from his medical training – he even avoided a neurology residency because, he says, "the definition of neurology practice was diagnose and adios." After six years in another biotech company, however, he "felt that SCI chose me," he says. "I became convinced that this was the right time to work on nerve repair – that it was not a quixotic venture."
|
Rebuilding Superman 
Biotech Applied Index
